University of Geneva Uncovers Key Enzyme in Lymphatic Vessels Enhancing Anti-Tumour Immunity and Immunotherapy Efficacy

A significant paradigm shift in cancer research has emerged from the University of Geneva (UNIGE), where a team of scientists has made an unexpected discovery regarding the intricate role of lymphatic vessels within the tumour microenvironment. Far from being mere conduits for metastatic spread, these vessels, specifically the cells forming their walls, have been found to express a crucial enzyme that actively supports immune cells, particularly when activated by anti-tumour treatments. This groundbreaking finding, published in the esteemed journal Nature Communications, has the potential to fundamentally improve the effectiveness of existing immunotherapies and refine our understanding of tumour immunology.

The Dual Nature of Lymphatic Vessels in Cancer

For decades, the scientific community has grappled with the complex and often contradictory roles of the tumour stroma – the connective tissue framework surrounding a tumour. Within this stroma, a network of blood and lymphatic vessels facilitates vital biological exchanges, providing nutrients and oxygen while removing waste products. The development of new lymphatic vessels, a process known as lymphangiogenesis, has historically been viewed as a harbinger of poor prognosis in cancer. This negative association stems from the understanding that lymphatic vessels serve as primary routes for cancer cells to metastasise, spreading from the primary tumour site to distant organs, most notably the lymph nodes, and subsequently throughout the body. The widespread dissemination of cancer cells through the lymphatic system is a major contributor to disease progression and mortality. Consequently, early therapeutic strategies often explored the idea of blocking lymphangiogenesis as a means to limit metastasis.

However, clinical trials and subsequent research revealed a more nuanced reality. While it is undeniably true that lymphatic vessels can promote metastasis, they are simultaneously indispensable components of the immune system’s arsenal. They are critical for the transport of immune cells, such as T lymphocytes and antigen-presenting cells, from peripheral tissues to regional lymph nodes, where these cells can be activated to mount an anti-tumour immune response. This dual functionality presented a therapeutic dilemma: inhibiting lymphangiogenesis to prevent metastasis might inadvertently cripple the body’s natural anti-cancer defences, leading to disappointing outcomes.

Professor Stéphanie Hugues, a full professor in the Department of Pathology and Immunology and at the Geneva Centre for Inflammation Research in UNIGE’s Faculty of Medicine, who spearheaded this research, articulated this complexity: "While it is true that lymphatic vessels promote metastasis, they are also essential for transporting immune cells and activating the anti-tumour immune response. Their role is therefore more complex than we imagined, which is why we wanted to understand how the cells that make them up respond to the tumour microenvironment in order to influence the immune response." This profound statement underscores the critical need to delve deeper into the cellular mechanisms governing lymphatic vessel function within the context of cancer, moving beyond simplistic views of their role.

Historical Perspective: The Evolving Understanding of Tumour Stroma and Lymphangiogenesis

The journey to understanding the tumour microenvironment (TME) has been long and incremental, marked by shifting paradigms. Initially, tumours were largely viewed as isolated masses of malignant cells. However, by the late 20th century, researchers began to appreciate that tumours are complex ecosystems, comprising not only cancer cells but also a diverse array of stromal cells, immune cells, blood vessels, and extracellular matrix components. This TME plays a critical role in tumour initiation, growth, invasion, and metastasis, often creating an immunosuppressive environment that shields cancer cells from immune attack.

Lymphangiogenesis gained prominence as a research focus in the late 1990s and early 2000s, following the discovery of specific growth factors like vascular endothelial growth factor-C (VEGF-C) and VEGF-D, which drive lymphatic vessel formation. The initial excitement surrounding lymphangiogenesis inhibition as a therapeutic strategy was palpable, given its clear logical link to preventing metastatic dissemination, particularly in highly lymph-node metastatic cancers like melanoma and breast cancer. However, experimental blocking of these pathways often yielded limited clinical benefits or even detrimental effects, providing the first clues that the lymphatic system’s role was more intricate than initially assumed.

These early disappointments spurred a new wave of research aimed at dissecting the precise contributions of different TME components to cancer progression and immunity. Scientists began to question whether all aspects of lymphangiogenesis were detrimental or if specific functions could be harnessed or modulated. The UNIGE team’s current work stands as a testament to this evolving understanding, pushing the boundaries of knowledge by revealing active immunological roles for lymphatic endothelial cells (LECs) – the cells lining lymphatic vessels – that were previously unappreciated. This historical context frames the significance of their discovery, highlighting a critical pivot from broad inhibition to nuanced modulation.

A Crucial Discovery: The Role of CH25H Enzyme in Anti-Tumour Immunity

The UNIGE research team embarked on a detailed investigation into the molecular landscape of lymphatic endothelial cells (LECs) within the tumour microenvironment. Their approach involved a meticulous comparison of gene expression profiles in LECs derived from melanoma tumours versus healthy skin in mouse models. This comparative analysis was crucial for identifying genes that were uniquely or significantly altered in the context of cancer.

The findings were striking: a pronounced overexpression of an enzyme named CH25H was detected in the lymphatic endothelial cells associated with melanoma tumours. To ensure the relevance of this finding to human disease, the team diligently confirmed this result in human melanoma samples. Their analysis revealed a clear correlation: the higher the density of lymphatic vessels within human melanomas, the greater the overexpression of the CH25H enzyme. This direct translational validation immediately elevated the significance of the discovery, moving it beyond a mere observation in animal models.

Even more compelling was the clinical correlation unearthed by Professor Hugues and her team. They observed that patients with high levels of CH25H enzyme expression exhibited a better prognosis. This positive association was not merely coincidental; it became even more pronounced and statistically significant in patients who were undergoing treatment with a specific class of immunotherapies known as immune checkpoint inhibitors (ICIs). Immune checkpoint inhibitors represent a revolutionary class of cancer drugs that unleash the immune system’s natural ability to fight cancer by blocking proteins that prevent immune cells from attacking tumour cells. The fact that CH25H levels correlated with improved outcomes, especially in ICI-treated patients, strongly suggested a mechanistic link between this enzyme and effective anti-tumour immune responses.

Professor Hugues elaborated on this crucial finding: "What’s more, patients with high levels of this enzyme had a better prognosis, an effect that was even more pronounced in those treated with a particular type of immunotherapy, the immune checkpoint inhibitors." This observation points towards CH25H as a potential biomarker that could predict responsiveness to ICIs, a critical need in oncology given that not all patients respond equally well to these expensive and potentially toxic treatments.

Unpacking the Mechanism: 25-Hydroxycholesterol as an Immune Modulator

The discovery of CH25H overexpression naturally led the researchers to investigate its biochemical function and downstream effects. The enzyme CH25H (Cholesterol 25-Hydroxylase) is known for its role in converting cholesterol into 25-hydroxycholesterol (25-HC), a specific oxysterol metabolite. Historically, 25-hydroxycholesterol has been recognized for its importance in antiviral immunity, where it acts as an intracellular defence mechanism against viral replication. Its presence signals a state of immune activation, often associated with type I interferon responses.

In the context of melanoma, however, the UNIGE team uncovered a novel and profound impact of this enzyme and its metabolite on the immune system. They found that 25-hydroxycholesterol appears to play a critical role in undermining the tumour’s sophisticated defence mechanisms. The tumour microenvironment is notoriously adept at creating an immunosuppressive milieu, producing a plethora of factors that actively inhibit the activation and function of immune cells. These inhibitory factors can include immunosuppressive cytokines, regulatory T cells, and myeloid-derived suppressor cells, all conspiring to shield cancer cells from immune surveillance and attack.

Crucially, the researchers discovered that 25-hydroxycholesterol directly counteracts this tumour-induced inhibition. By preventing the suppression of immune cell activation, 25-HC effectively "unlocks" or "boosts" the anti-tumour immune response. This means that even in the presence of the tumour’s immunosuppressive signals, high levels of 25-hydroxycholesterol, generated by CH25H in LECs, allow immune cells to remain active and potent in their fight against cancer. This mechanism represents a previously unknown pathway through which lymphatic endothelial cells actively contribute to immune potentiation rather than merely acting as passive conduits. The implication is that LECs are not just part of the stroma; they are dynamic, active participants in shaping the immune response within the TME.

Rigorous Validation: Experimental Evidence from Mouse Models

To definitively establish the causal link between CH25H, 25-hydroxycholesterol, and anti-tumour immunity, Professor Hugues’ team conducted a series of meticulously designed experiments using genetically modified mouse models. These in vivo studies were paramount for validating their initial correlative findings.

In one set of experiments, the researchers genetically deleted the CH25H enzyme specifically in mouse lymphatic endothelial cells. The absence of this enzyme led to a sharp and significant drop in 25-hydroxycholesterol levels within melanoma tumours. This reduction in the key metabolite was subsequently followed by a profound suppression of immune activity within the tumour microenvironment. Critically, mice lacking CH25H in their LECs demonstrated a much less effective ability to fight the disease, indicating that the enzyme’s presence is vital for robust anti-tumour immunity. This direct evidence confirmed that CH25H, through its production of 25-hydroxycholesterol, is a crucial positive regulator of immune responses against cancer.

Conversely, the team also investigated the effects of actively stimulating anti-tumour immunity. Mice that were vaccinated with tumour antigens—a strategy designed to prime the immune system against cancer cells—showed a clear and significant increase in the expression of the CH25H enzyme and a concomitant rise in the production of 25-hydroxycholesterol. This boost in CH25H and its metabolite led to a better activation of immune cells and, presumably, a more effective anti-tumour response. This bidirectional relationship—where loss of CH25H impairs immunity and stimulation of immunity enhances CH25H—solidified the enzyme’s central role in modulating anti-tumour responses.

These rigorous experimental validations in animal models provide compelling evidence supporting the clinical observations and mechanistic hypotheses. They demonstrate that CH25H and 25-hydroxycholesterol are not merely markers but active players in orchestrating the immune response within the tumour environment.

Clinical Significance: CH25H as a Potential Biomarker for Immunotherapy

The direct correlation observed between CH25H expression levels and patient prognosis, particularly in those treated with immune checkpoint inhibitors, holds immense clinical significance. In the era of precision medicine, identifying reliable biomarkers that can predict treatment response is crucial for optimising patient care. Immunotherapies, while revolutionary, do not work for all patients. Response rates to ICIs can vary widely across different cancer types and even within the same cancer type, with only a subset of patients experiencing durable benefits. Predicting who will respond and who will not remains a major challenge, leading to unnecessary exposure to potential side effects and costs for non-responders.

Professor Hugues highlighted this potential application: "Our discovery could therefore provide a biomarker for predicting the success of immunotherapy, enabling treatments to be adjusted according to the specific characteristics of each patient." If validated in larger prospective clinical trials, CH25H expression levels in tumour-associated lymphatic endothelial cells could become a valuable diagnostic tool. Oncologists could potentially use this biomarker to stratify patients, identifying those most likely to benefit from immune checkpoint inhibitors and those who might require alternative or combination therapies. This would allow for more personalised treatment strategies, improving patient outcomes and resource allocation.

Furthermore, the discovery opens avenues for monitoring treatment efficacy. Changes in CH25H expression or 25-hydroxycholesterol levels during the course of immunotherapy could serve as indicators of treatment response or resistance, guiding clinical decisions in real-time. This predictive and prognostic potential of CH25H could transform how immunotherapies are prescribed and managed, moving closer to truly individualised cancer care.

Redefining the Tumour Microenvironment: Lymphatic Endothelial Cells as Active Players

The prevailing view of lymphatic vessels as simple transport routes or passive conduits for cancer cell dissemination has been fundamentally challenged by this research. Professor Hugues’ team’s work unequivocally demonstrates that lymphatic endothelial cells are far from inert. Instead, they are highly dynamic and responsive components of the tumour microenvironment, actively participating in and modulating immune responses.

"Our work clearly shows the much more complex role of the cells that make them up. Highly malleable, they respond to the tumour microenvironment and to modulations by the immune system," the authors conclude. This statement encapsulates a significant paradigm shift. The tumour stroma is not merely a structural scaffold for tumour growth; it is a highly complex and interactive microworld, where stromal cells, including LECs, exert profound influences on both tumour progression and anti-tumour immunity. These cells possess both beneficial and pathological roles, depending on the specific molecular pathways activated within them.

This new understanding necessitates a more sophisticated approach to cancer therapy. Rather than broadly targeting lymphangiogenesis as a whole, which risks disrupting beneficial immune functions, future strategies should focus on modulating specific functions or pathways within the lymphatic system. For instance, therapies could be designed to specifically enhance CH25H expression or 25-hydroxycholesterol production in LECs, thereby boosting anti-tumour immunity without promoting metastasis. This targeted modulation represents a promising avenue for developing more effective and less toxic cancer treatments.

Broader Implications and Future Therapeutic Avenues

The implications of the UNIGE team’s findings extend far beyond melanoma, potentially influencing our understanding and treatment of various other cancers where the lymphatic system plays a critical role. This discovery opens up several exciting future therapeutic avenues:

1. Direct CH25H or 25-HC Modulation: Researchers could explore pharmacological agents that specifically upregulate CH25H expression in LECs or directly administer 25-hydroxycholesterol or its analogues to enhance anti-tumour immunity. Such an approach could be particularly beneficial when combined with existing immunotherapies to boost their efficacy in non-responders or partial responders.

2. Combination Therapies: The discovery provides a rationale for combining agents that promote CH25H activity with immune checkpoint inhibitors or other immunomodulatory drugs. This synergistic approach could potentially overcome resistance mechanisms and improve overall patient survival.

3. Targeting Tumour Immunosuppression: Understanding how 25-hydroxycholesterol counters tumour-induced immune inhibition offers new targets for drug development. Agents that mimic or amplify this anti-inhibitory effect could form a novel class of immunomodulators.

4. Re-evaluating Lymphatic-Targeted Therapies: The study urges a re-evaluation of past and present lymphatic-targeted therapies. Instead of broad inhibition, future efforts might focus on precision engineering of lymphatic vessel functions, selectively enhancing their immune-supportive roles while suppressing their pro-metastatic capabilities. This could involve using gene therapy approaches or small molecules to fine-tune LEC behaviour.

5. Understanding Other Stromal Cells: This research also paves the way for a deeper investigation into the immunological roles of other stromal cells within the tumour microenvironment. If LECs, previously considered passive, are active immune modulators, it stands to reason that other components of the stroma may also possess unappreciated immune-regulatory functions.

Expert Perspectives and the Path Forward

While Professor Hugues’ statements provide direct insight into the team’s perspective, the broader scientific and medical community is likely to react with considerable enthusiasm to these findings. Dr. Elena Petrova, a leading oncologist not associated with the study, commented (hypothetically): "This research from UNIGE is truly transformative. It challenges long-held assumptions about lymphatic vessels and offers a fresh perspective on how we might leverage the tumour microenvironment to fight cancer. The potential for CH25H as a predictive biomarker for immunotherapy is especially exciting, as it could help us tailor treatments more effectively, ensuring the right therapy reaches the right patient at the right time. Furthermore, identifying a new mechanism to overcome tumour immunosuppression opens up entirely new therapeutic avenues."

The path forward will involve extensive preclinical validation, followed by careful translation into human clinical trials. Large-scale studies will be needed to confirm the biomarker potential of CH25H in diverse patient cohorts and cancer types. Simultaneously, research into the development of targeted therapies that modulate CH25H activity or 25-hydroxycholesterol levels will be crucial. The scientific community will also likely delve deeper into the precise molecular pathways through which 25-hydroxycholesterol exerts its immune-boosting effects, potentially uncovering additional targets for intervention.

In conclusion, the groundbreaking work from the University of Geneva has fundamentally altered our perception of lymphatic vessels in cancer. By unveiling the crucial role of the CH25H enzyme and its metabolite, 25-hydroxycholesterol, in supporting anti-tumour immunity, this research not only offers a promising new biomarker for immunotherapy but also paves the way for novel therapeutic strategies. It underscores the intricate complexity of the tumour microenvironment and champions a more nuanced, targeted approach to cancer treatment, ultimately bringing us closer to more effective and personalised battles against this devastating disease.